OMC
RPRX icon

Overbrook Management Corp’s Royalty Pharma RPRX Stock Holding History

Overbrook Management Corp’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Hold
38,208
– – 0.32% 38
2026
Q1 		$1.83M Sell
38,208
-5,000
-12% -$219K 0.35% 34
2025
Q4 		$1.67M Hold
43,208
– – 0.29% 34
2025
Q3 		$1.52M Sell
43,208
-5,000
-10% -$181K 0.27% 33
2025
Q2 		$1.74M Sell
48,208
-10,200
-17% -$338K 0.32% 31
2025
Q1 		$1.82M Sell
58,408
-60,000
-51% -$1.9M 0.43% 31
2024
Q4 		$3.02M Sell
118,408
-22,500
-16% -$597K 0.65% 30
2024
Q3 		$3.99M Sell
140,908
-59,504
-30% -$1.65M 0.91% 27
2024
Q2 		$5.28M Sell
200,412
-8,937
-4% -$248K 1.33% 26
2024
Q1 		$6.36M Sell
209,349
-10,328
-5% -$304K 1.71% 23
2023
Q4 		$6.17M Sell
219,677
-79,035
-26% -$2.17M 1.25% 22
2023
Q3 		$8.11M Sell
298,712
-255,005
-46% -$7.57M 1.89% 22
2023
Q2 		$17M Sell
553,717
-25,066
-4% -$849K 4.04% 10
2023
Q1 		$20.9M Sell
578,783
-30,569
-5% -$1.13M 5.46% 5
2022
Q4 		$24.1M Sell
609,352
-19,550
-3% -$816K 7% 4
2022
Q3 		$25.3M Sell
628,902
-71,169
-10% -$3.04M 7.18% 3
2022
Q2 		$29.4M Sell
700,071
-23,179
-3% -$950K 8.51% 2
2022
Q1 		$28.2M Sell
723,250
-5,875
-0.8% -$231K 6.25% 2
2021
Q4 		$29.1M Sell
729,125
-56,007
-7% -$2.18M 5.86% 3
2021
Q3 		$28.4M Buy
785,132
+28,011
+4% +$1.09M 6.16% 2
2021
Q2 		$31M Sell
757,121
-14,034
-2% -$597K 6.49% 2
2021
Q1 		$33.6M Sell
771,155
-7,356
-0.9% -$349K 7.48% 2
2020
Q4 		$39M Buy
778,511
+670,759
+623% +$28.5M 9.51% 1
2020
Q3 		$4.53M Buy
+107,752
New +$4.62M 1.05% 24

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Overbrook Management Corp's RPRX Position: Q2 2026 in Review

Overbrook Management Corp held its Royalty Pharma (RPRX) position steady in Q2 2026 at 38,208 shares worth $2.14M. The position accounts for 0.32% of the portfolio, ranked #38.

Overbrook Management Corp first reported a position in RPRX in Q3 2020 and has held it in 24 quarters since. The position peaked at $39M in Q4 2020. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Overbrook Management Corp held 38,208 shares of Royalty Pharma worth $2.14M as of Q2 2026.
  • Overbrook Management Corp left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up 0.32% of Overbrook Management Corp's portfolio in Q2 2026, its #38 holding.
  • Overbrook Management Corp first reported a position in Royalty Pharma in Q3 2020 and has held it in 24 quarters since.
  • Overbrook Management Corp's Royalty Pharma position peaked at $39M in Q4 2020.
  • 641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Overbrook Management Corp's 13F filing for Q2 2026, filed 30 Jul 2026.